Erythemato-telangiectatic rosacea: analysis of effectivity of treatment by flavonoid-rich topical agents

Cover Page

Abstract


Rosacea is a common non-infectious disease with intricate aetiology involving endogenous, systemic or local, and environmental factors. Vascular changes may play a major role in rosacea pathogenesis. Chrysanthellum indicum extract contains a unique combination of component which has a beneficial effect on vascular wall permeability and increases the mechanical resistance of capillaries. The aim of the study is to investigate clinical and epidemiologic features of rosacea as well as to evaluate the efficacy and tolerability of external medication - flavonoid-rich plant extract-based cream Ruboril - in patients with erythemato-telangiectatic subtype of rosacea. Material and methods. We observed 52 patients (16 male and 36 female) aged from 23 to 69 with erythemato-telangiectatic subtype of rosacea. The diagnosis was established on the base of clinical presentation with regard to major and minor diagnostic criteria. In order to evaluate the efficacy of topical therapy with Ruboril cream a scale from 0 to 3 was used assessing the severity grade of erythema and teleangiectasias before treatment and after the 4th, 8th and 12th week of therapy. Results. Women were more often affected than men (69%). Patients of the age group from 40 years prevailed (75%). Fitzpatrick skin phototype II was revealed in 30 (58%) of patients. The most common provoking factors were meteorological (77%), emotional stress (67%), sauna/hot baths or alcohol (66%), hot drinks (48%). The prevailing areas of affection were cheeks (98%), forehead (54%), chin (48%), nose (52%). Moderate erythema was observed in 29 (56%) of patients, severe erythema in 15 (29%). Moderate grade of telangiectasias was registered in 30 (58%) of patients, numerous telangiectasias in 16 (31%). Topical application of cream Ruboril allowed to achieve good immediate results: the severity of erythema was reduced by 63%, the manifestation of telangiectasias decreased by 63%. Conclusion. Clinico-epidemiologic features of patients with erythemato-telangiectatic subtype of rosacea are as follows: erythematous and telangiectatic eruption on the cheeks, nose, and chin, weather and emotional influences, predominance of the female gender, skin phototype II, age > 40 years. The external medication Ruboril showed its high efficacy and safety in the treatment of patients with erythemato-telangiectatic subtype of rosacea which allowed to achieve good immediate results with erythema severity reduction of 63% and the decrease in the manifestation of telangiectasias of 63%.

About the authors

V. P. Adaskevich

Vitebsk State Medical University

Author for correspondence.
Email: admin@vsmu.by

Russian Federation

V. V. Saprykova

Medincenter, Department of Aesthetic Medicine

Email: noemail@neicon.ru

Russian Federation

M. V. Adaskevich

Saint Petersburg State University

Email: noemail@neicon.ru

Russian Federation

References

  1. Tan J., Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69 (6 Suppl 1): 27-35.
  2. National Rosacea Society. If you have rosacea, you’re not alone. http://www.rosacea.org/patients/index.php. Accessed 28 Apr 2014.
  3. Steinhoff M., Buddenkotte J., Aubert J. et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 2-11.
  4. Wilkin J., Dahl M., Detmar M., Drake L., Feinstein A., Odom R. et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46 (4): 584-7.
  5. Elewski B.E., Draelos Z., Dréno B. et al. Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25 (2): 188-200.
  6. Yamasaki K., Gallo R.L. The molecular pathology of rosacea. J Dermatol Sci 2009; 55 (2): 77-81.
  7. Meyer-Hoffert U., Schroder J.M. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 2011; (15): 16-23.
  8. Yamasaki K., Gallo R.L. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc 2011; (15): 12-15.
  9. Adaskevich V.P. Diagnosticheskie indeksy v dermatologii. M: Izdatel'stvo Panfilova; 2014.
  10. Scharschmidt T.C., Yost J.M., Truong S.V. et al. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. Arch Dermatol 2011; 147 (1): 123-126.
  11. Schwab V.D., Sulk M., Seeliger S. et al. Neurovascular and Neuroimmune Aspects in the Pathophysiology of Rosacea. J Investig Dermatol Symp Proc 2011; 15 (1): 53-62.
  12. Chosidow O., Cribier B. Epidemiology of rosacea: updated data. Ann Dermatol Venereol 2011; 138 (3): 179-183.
  13. Sulk M., Seeliger S., Aubert J. et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol 2012; 132 (4): 1253-1262.
  14. Del Rosso J.Q. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol 2012; 5 (3): 26-36.
  15. Del Rosso J.Q. Management of facial erythema of rosacea: what is the role of topical alpha-adrenergic receptor agonist therapy? J Am Acad Dermatol 2013; 69 (6 Suppl 1): 44-56.
  16. Rigopoulos D., Kalogeromitros D., Gregoriou S. et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea JEADV 2005; 19 (5): 564-568.

Statistics

Views

Abstract - 753

PDF (Russian) - 432

PlumX

Dimensions


Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies